HC Wainwright Estimates Urogen Pharma Q3 Earnings

Urogen Pharma (NASDAQ:URGN) – Equities research analysts at HC Wainwright issued their Q3 2027 earnings estimates for shares of Urogen Pharma in a research note issued to investors on Thursday, April 23rd. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $0.27 per share for the quarter. The consensus estimate for Urogen Pharma’s current full-year earnings is ($1.45) per share.

URGN has been the topic of several other research reports. D. Boral Capital restated a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research report on Tuesday, March 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday. Jefferies Financial Group assumed coverage on shares of Urogen Pharma in a report on Friday, April 10th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Monday, March 2nd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.13.

Urogen Pharma Price Performance

NASDAQ URGN opened at $24.11 on Friday. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $30.00. The stock has a market capitalization of $1.17 billion, a PE ratio of -7.53 and a beta of 1.43. The company’s 50 day simple moving average is $20.11 and its two-hundred day simple moving average is $21.13.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.12. The firm had revenue of $37.84 million during the quarter, compared to analysts’ expectations of $39.92 million.

Hedge Funds Weigh In On Urogen Pharma

Several institutional investors and hedge funds have recently made changes to their positions in URGN. Paradigm Biocapital Advisors LP bought a new position in shares of Urogen Pharma during the 3rd quarter valued at $84,111,000. Soleus Capital Management L.P. bought a new stake in Urogen Pharma in the 2nd quarter worth $29,934,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Urogen Pharma in the 4th quarter worth $26,350,000. MPM Bioimpact LLC grew its holdings in Urogen Pharma by 597.3% in the 4th quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock worth $22,047,000 after acquiring an additional 806,378 shares during the last quarter. Finally, TCG Crossover Management LLC bought a new stake in Urogen Pharma in the 3rd quarter worth $14,311,000. Institutional investors own 91.29% of the company’s stock.

Insider Buying and Selling at Urogen Pharma

In related news, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $147,261.51. Following the transaction, the general counsel owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. This trade represents a 12.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Schoenberg sold 7,373 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $145,174.37. Following the transaction, the insider directly owned 144,985 shares in the company, valued at approximately $2,854,754.65. This represents a 4.84% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is currently owned by company insiders.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.